within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01B_Antimalarials.P01BB01_Proguanil;

model Proguanil
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.75,
    Cl = 6.3888888888888885e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.342,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.006333333333333333,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Proguanil</td></tr><tr><td>ATC code:</td><td>P01BB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>342</td><td>L</td></tr>
    <tr><td>clearance:</td><td>23</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Proguanil is an antimalarial drug, primarily used for the prevention and treatment of malaria, often in combination with atovaquone. It acts by inhibiting dihydrofolate reductase in the malaria parasite. Proguanil is still approved and in clinical use for malaria prophylaxis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose of proguanil.</p><h4>References</h4><ol><li><p>Hussein, Z, et al., &amp; Canfield, CJ (1996). Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. <i>British journal of clinical pharmacology</i> 42(5) 589–597. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1996.tb00114.x\">10.1111/j.1365-2125.1996.tb00114.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8951190/\">https://pubmed.ncbi.nlm.nih.gov/8951190</a></p></li><li><p>Helsby, NA, et al., &amp; Breckenridge, AM (1990). The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. <i>British journal of clinical pharmacology</i> 30(4) 593–598. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1990.tb03818.x\">10.1111/j.1365-2125.1990.tb03818.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2291871/\">https://pubmed.ncbi.nlm.nih.gov/2291871</a></p></li><li><p>McGready, R, et al., &amp; Nosten, F (2003). The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. <i>European journal of clinical pharmacology</i> 59(7) 545–552. DOI:<a href=\"https://doi.org/10.1007/s00228-003-0652-9\">10.1007/s00228-003-0652-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12955371/\">https://pubmed.ncbi.nlm.nih.gov/12955371</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P01BB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Proguanil;
